Transcript British Heart Valve Society Carcinoid Heart Disease
British Heart Valve Society Carcinoid Heart Disease
Dr C Hayward MB BChir MRCP , Dr S Bhattacharyya MD MRCP, Dr J Davar MD PhD Royal Free Hospital, London, UK
Case Presentation Clinical History
• 60 year old female.
• 6 month history of flushing, diarrhoea, fatigue and dyspnoea on exertion. NYHA Class III at presentation.
Investigations
• CT abdomen: multiple liver metastases and a small bowel mesenteric mass. Liver Biopsy: consistent with low grade carcinoid tumour.
• 24 hour Urinary 5-HIAA: 800µmol/24 hours.
Cardiac Investigations
• ECG – sinus tachycardia. Normal axis
.
• CXR – Cardiothoracic ratio > 50%. • Echocardiogram: – Right Ventricle: dilated and mildly impaired (TAPSE 13cm).
– Tricuspid Valve: severe “free flowing” tricuspid regurgitation.
– Pulmonary Valve: severe pulmonary regurgitation, moderate pulmonary stenosis. – NT-proBNP: 700 pg/ml.
Management Medical
•Reduction of peripheral oedema with diuretics.
Valve Surgery
•Replacement of tricuspid and pulmonary valve: Pulmonary homograft.
Pericardial tissue valve – tricuspid valve.
Length of hospital stay 5 days. Required permanent pacemaker for complete heart block.
Outcome 6 months post surgery
•Diuretics weaned off.
•Functional NYHA Class I. Climb > 5 flights of stairs.
Clinical Manifestations
• Carcinoid syndrome consists of a triad: flushing, diarrhoea and bronchospasm.
• Between 20-50% of all patients with carcinoid syndrome will develop carcinoid heart disease.
• Vasoactive substances such as 5-hydroxytryptamine produced by neoplastic cells are able to travel to the right heart via the hepatic vein/IVC and are thought to be responsible for deposition of endocardial plaques of fibrous tissue.
• Classically patients develop signs and symptoms of right heart failure: fatigue, oedema and ascites.
Pathology – “Carcinoid Plaque”
• Right-sided lesions more common than left. • Preferential right-sided involvement due to inactivation of vasoactive substances by lungs.
• 5–10% have left-sided valvular pathology due to either high tumour load, bronchial carcinoid or patent foramen ovale.
• Plaque - composed of smooth muscle cells + myofibroblasts forming white fibrous layer (arrow) lining endocardial surface of cardiac valves superficial to normal valve
Echocardiographic Features – Tricuspid Valve
• Typically thickened, retracted, valve leaflets. Leaflets do not co-apt (arrow).
• Anatomical features leads to predominantly tricuspid regurgitation (TR).
• Classical “Dagger” shaped Doppler profile of severe TR (arrow).
Echocardiographic Features – Pulmonary Valve
• Fixed, thickened cusps (arrow).
• Non-coaptation of cusps (*).
• Predominantly pulmonary stenosis with varying degrees of regurgitation (arrow).
Biochemical Markers
• Elevated urinary 5-hydroxyindolacetic acid is a highly sensitive but poorly specific maker of carcinoid heart disease.
• NT-proBNP > 260pg/ml has greater than 90% sensitivity and negative predictive value for significant carcinoid heart disease. This may allow its use as a screening test.
• NT-proBNP also correlated with disease severity and NYHA Class .
Management
Medical Management
•Poor outcome when managed medically.
•3 year survival 68% without cardiac involvement compared to 31% with cardiac involvement.
•Diuretics mainstay of therapy.
Valve Surgery
•High peri-operative risk (10% 20% depending on institution).
•Valve replacement improves symptom status (functional NYHA Class).
•Emerging data suggest may improve prognosis.
Conclusions
• Carcinoid heart disease = common complication of carcinoid syndrome but is a rare cause of all acquired valvular heart disease • 5-HT is produced by metastatic tumour cells in the liver → deposition of endocardial plaques.
• Right sided valvular dysfunction is common and presents with characteristic echocardiographic appearances. Left sided valve lesions in 5-10% of cases of carcinoid heart disease.
• Medical management alone is associated with poor survival.
• Valve surgery improves symptoms and may improve prognosis.
Further Reading
1.
2.
3.
4.
5.
6.
Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid Heart Disease.
Circulation
2007; 116:2860-2865.
Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E.
Relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities.
Circulation
1988;77:264-269.
Bhattacharyya S, Toumpanakis D, Burke M, Taylor AM, Caplin ME, Davar J.
Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI.
111.
Circ Cardiovasc Imaging
2010:3:103 Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
J Clin Oncol
. 2009;27:4293-4299.
Bhattacharyya S, Toumpanakis C, Caplin M, Davar J. Usefulness of N Terminal Brain Natriuretic Peptide As A Biomarker Of The Presence Of Carcinoid Heart Disease.
942.
American Journal of Cardiology
2008;102:938 Moller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM.
Prognosis of carcinoid heart disease: An analysis of 200 cases over two decades.
Circulation
2005;112:3320-3327.